#Norway #Oslo #Radspherin #Oncoinvent #OvarianCancer

Oncoinvent ASA Half-Yearly Report Overview

Oncoinvent ASA has marked notable progress in its ongoing clinical trials treating ovarian cancer, as detailed in the latest half-yearly report. With a strong emphasis on both financial discipline and advancing its Phase 2 program, the company aims to enhance its impact on cancer therapies.

Highlights of the First Half of 2025

In the report, which covers the first half of 2025, several key achievements were underscored:

• - Radspherin® Progress: The company has received positive final data from its Phase 1/2a trial focusing on colorectal cancer patients. Moreover, encouraging interim data after 18 months from the Phase 1 trial in ovarian cancer patients adds to their optimistic outlook.
• - Safety and Efficacy Readouts: Oncoinvent has successfully conducted a safety lead-in cohort, paving the way for the randomization of Phase 2 trials involving ovarian cancer patients. Regulatory approvals for new sites to conduct these randomized trials have been secured, with onboarding expected to be completed by the end of 2025.
• - Financial Discipline: Operating expenses have been cut by an impressive 28% compared to the previous year, demonstrating a solid commitment to financial management. Additionally, the company has announced a merger with BerGenBio, alongside a fully guaranteed rights issue totaling NOKm 130.

Financial Presentation and Corporate Updates

CEO Øystein Soug and CFO Tore Kvam presented these results during a webcast on August 27, 2025. They discussed not only the positive clinical trial advancements but also financial strategies that emphasize sustainable growth and investor confidence. A recording of the presentation is available for those who missed the live event.

About Oncoinvent and Radspherin®

Oncoinvent is a dynamic clinical-stage biotechnology company that specializes in developing innovative radiopharmaceutical therapies to combat cancer. The flagship product Radspherin® employs radium-224, an alpha-emitting radionuclide. This therapy is specifically designed to target micrometastases following surgical interventions, thereby leveraging modern radiopharmaceutical advantages without the complexities entailed by biological targeting.

Currently, Radspherin® is undergoing evaluation in a clinical program addressing two main indications: ovarian cancer and colorectal cancer. The early clinical efficacy results reported have been encouraging, with no severe safety or toxicity concerns to date.

Manufacturing Capabilities

The production of drug products for clinical trials is carried out at Oncoinvent's state-of-the-art facility located in Nydalen, Oslo. Their rigorous manufacturing processes ensure that high-quality products are consistently available for ongoing trials.

Conclusion

With a clear focus on advancing its clinical programs and financial discipline, Oncoinvent ASA is strategically positioned to impact cancer treatment. The prospects surrounding Radspherin® continue to generate enthusiasm within the medical community, and the company's financial maneuvers reflect a robust approach to sustainable growth in a competitive landscape. As the firm pushes forward, stakeholders remain optimistic about further developments in their clinical trials and overall business strategy.